FDA Approves Atezolizumab as Adjuvant Treatment for NSCLC

On October 15, 2021, U.S. the Food and Drug Administration (FDA) approved atezolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. 

Read the FDA announcement.

Read Roche's announcement.

Posted 10/18/2021